Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

Jing GU; Yan WANG; Wei SUN; Weifeng ZHAO; Jianhe GAN

doi:10.3969/j.issn.1001-5256.2021.02.012

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 304-308

PDF( 2025 KB)

Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.02.012

Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

Received Date: 2020-08-07
Accepted Date: 2020-09-03
Published Date: 2021-02-20

Abstract

Abstract

Objective To investigate the value of interleukin-32 (IL-32) combined with Model for End-Stage Liver Disease (MELD) in predicting the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF). Methods A total of 92 patients with HBV-ACLF who were hospitalized in The First Affiliated Hospital of Soochow University from January 2015 to December 2018 were enrolled, and according to the follow-up results at 3 months after diagnosis, the patients were divided into survival group with 40 patients and death group with 52 patients. ELISA was used to measure the serum level of IL-32. Clinical data of the patients were collected, including age, sex, underlying diseases, major complications, white blood cell count (WBC), platelet count (PLT), hematocrit (HCT), total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (Alb), serum creatinine (SCr), prothrombin time (PT), international normalized ratio (INR), and HBV DNA. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups; a Pearson correlation analysis was performed for IL-32 and other variables; a binary logistic regression analysis was performed to investigate the independent risk factors for the prognosis of patients with HBV-ACLF. The receiver operating characteristic(ROC) curve(AUC) was used to evaluate the value of IL-32 combined with MELD score in predicting the prognosis of patients with HBV-ACLF. The normal Z test was used for comparison of AUC. Results There were significant differences between the two groups in HCT, PLT, TBil, SCr, PT, INR, HBV DNA, IL-32, and MELD score (all P < 0.05). IL-32 was positively correlated with TBil (r=0.952, P < 0.001) and MELD score (r=0.850, P < 0.001). IL-32 (odds ratio [OR]=1.137, 95% confidence interval [CI]: 1.040-1.243, P=0.005) and MELD score (OR=1.055, 95% CI: 1.001-1.109, P=0.025) were independent risk factors for the death of HBV-ACLF patients. IL-32 combined with MELD score had the highest value in predicting the prognosis of patients with HBV-ACLF (AUC=0.992, 95% CI: 0.981-1.000), with a significantly higher AUC than IL-32 (0.992 vs 0.984, Z=2.265, P < 0.05) and MELD score (0.992 vs 0.877, Z=3.182, P < 0.05). Conclusion Both IL-32 and MELD score can predict the prognosis of patients with HBV-ACLF, and the combination of these two indicators has a better predictive value.
- Hepatitis B Virus,
- Acute-On-Chronic Liver Failure,
- Interleukins,
- Prognosis

FullText(HTML)

References(24)

References

[1]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3
[2]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artifical Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.007 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007
[3]	LI H, JIA YN, HE Q, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. Ogran Transplantation, 2020, 11(3): 344-349. (in Chinese) DOI: 10.3969/j.issn.1674-7445.2020.03.004 李瀚, 贾亚男, 贺强, 等. 危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展[J]. 器官移植, 2020, 11(3): 344-349. DOI: 10.3969/j.issn.1674-7445.2020.03.004
[4]	SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391. DOI: 10.1053/j.gastro.2018.12.007
[5]	XU J, HUANG M. Predictive value of plasma diamine oxidase concentration combined with iMELD score on short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure[J/CD].Chin J Liver Dis (Electronic Version), 2020, 12(2): 68-75. (in Chinese) 许俊, 黄敏. 血浆二胺氧化酶联合iMELD评分对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的预测价值[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(2): 68-75.
[6]	ALBILLOS A, LARIO M, ÁLVAREZ-MON M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance[J]. J Hepatol, 2014, 61(6): 1385-1396. DOI: 10.1016/j.jhep.2014.08.010
[7]	RIBEIRO-DIAS F, SAAR GOMES R, de LIMA SILVA LL, et al. Interleukin 32: A novel player in the control of infectious diseases[J]. J Leukoc Biol, 2017, 101(1): 39-52. DOI: 10.1189/jlb.4RU0416-175RR
[8]	XU Q, PAN X, SHU X, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver[J]. J Infect, 2012, 65(4): 336-342. DOI: 10.1016/j.jinf.2012.05.009
[9]	ZHANG WJ, ZHAO LJ, WU JZ. Value of MELD、AARC、COSSH scoring systems in evaluating the 90-day prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(4): 813-817. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.04.021 张文佳, 赵丽娟, 吴基洲. MELD、AARC、COSSH评分系统对乙型肝炎相关慢加急性肝衰竭90天预后的评估价值[J]. 临床肝胆病杂志, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021
[10]	ZHAO RH, SHI Y, ZHAO H, et al. Acute-on-chronic liver failure in chronic hepatitis B: An update[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(4): 341-350. DOI: 10.1080/17474124.2018.1426459
[11]	WU W, YAN H, ZHAO H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: Differentiate it from No-ACLF[J]. Liver Int, 2018, 38(2): 248-257. DOI: 10.1111/liv.13504
[12]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740
[13]	SOLÉ C, SOLÀ E. Update on acute-on-chronic liver failure[J]. Gastroenterol Hepatol, 2018, 41(1): 43-53. DOI: 10.1016/j.gastrohep.2017.05.012
[14]	DALI-YOUCEF N, VIX M, COSTANTINO F, et al. Interleukin-32 contributes to human nonalcoholic fatty liver disease and insulin resistance[J]. Hepatol Commun, 2019, 3(9): 1205-1220. DOI: 10.1002/hep4.1396
[15]	GUI M, ZHANG H, ZHONG K, et al. Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis[J]. Asian Pac J Allergy Immunol, 2013, 31(1): 73-78.
[16]	YANG Z, SHI L, XUE Y, et al. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease[J]. Clin Chim Acta, 2019, 497: 104-109. DOI: 10.1016/j.cca.2019.07.019
[17]	DI BENEDETTO P, GUGGINO G, MANZI G, et al. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension[J]. Arthritis Res Ther, 2020, 22(1): 127. DOI: 10.1186/s13075-020-02218-8
[18]	KOEKEN V, VERRALL AJ, ARDIANSYAH E, et al. IL-32 and its splice variants are associated with protection against Mycobacterium tuberculosis infection and skewing of Th1/Th17 cytokines[J]. J Leukoc Biol, 2020, 107(1): 113-118. DOI: 10.1002/JLB.4AB0219-071R
[19]	ZOU Y, BAO J, PAN X, et al. NKP30-B7-H6 interaction aggravates hepatocyte damage through up-regulation of interleukin-32 expression in hepatitis B virus-related acute-on-chronic liver failure[J]. PLoS One, 2015, 10(8): e0134568. DOI: 10.1371/journal.pone.0134568
[20]	TIAN ZJ, SHEN Y, LI XR, et al. Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers[J]. J Infect Public Health, 2019, 12(1): 7-12. DOI: 10.1016/j.jiph.2018.06.006
[21]	LI ZY, YANG ST, ZHAO CY, et al. Analysis of prognostic risk factors and establishment of prognosis model in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Chin J Infect Dis, 2019, 37(12): 737-741. (in Chinese) DOI: 10.3760/cma.j.issn.1000-6680.2019.12.004 李子月, 杨士田, 赵彩彦, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者预后危险因素分析及预后模型建立[J]. 中华传染病杂志, 2019, 37(12): 737-741. DOI: 10.3760/cma.j.issn.1000-6680.2019.12.004
[22]	ZHANG H, SHI XX, ZENG YL, et al. Clinical study on short-term prognostic value of serum IL-8 level in patients with HBV related acute-on-chronic liver failure[J]. Infect Dis Info, 2020, 33(2): 136-139. (in Chinese) DOI: 10.3969/j.issn.1007-8134.2020.02.009 张鸿, 石新星, 曾义岚, 等. 血清IL-8预测HBV相关慢加急性肝衰竭患者短期预后的临床研究[J]. 传染病信息, 2020, 33(2): 136-139. DOI: 10.3969/j.issn.1007-8134.2020.02.009
[23]	WANG J, WANG Q, GUAN SH, et al. Expression and clinical significance of IL-26 in hepatitis B virus-associated acute-on-chronic liver failure[J]. Acta Universitatis Medicinalis Anhui, 2020, 55(4): 612-617. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE202004025.htm 汪静, 王琴, 管世鹤, 等. 白细胞介素-26在乙型肝炎相关慢加急性肝衰竭患者中的表达及临床意义[J]. 安徽医科大学学报, 2020, 55(4): 612-617. https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE202004025.htm
[24]	FISCHER J, SILVA TE, SOARES E SILVA PE, et al. From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis[J]. Cytokine, 2017, 91: 162-169. DOI: 10.1016/j.cyto.2016.12.017

Relative Articles

[1]	Daqing LIU, Yan HUANG, Jianhe GAN. Value of serum creatinine-to-cystatin C ratio in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 264-270. doi: 10.12449/JCH240208
[2]	Wenling LUO, Yu ZENG, Xuemei ZHANG, Yunjian SHENG. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(10): 1985-1991. doi: 10.12449/JCH241010
[3]	Xiaohua LIU, Shujuan YANG, Yushan LIU, Juan LI, Qiao ZHANG, Yamin WANG, Taotao YAN, Yuan YANG, Yingren ZHAO, Yingli HE. Value of peripheral blood lymphocyte count in evaluating the short－term prognosis of patients with acute－on－chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2383-2389. doi: 10.3969/j.issn.1001-5256.2023.10.016
[4]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[5]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[6]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[7]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[8]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[9]	Xinyi GAO, Li CHEN, Jianhe GAN. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(5): 1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019
[10]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[11]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[12]	Li Chen, Tan JunYuan, Xu Xiang. Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1960-1965. doi: 10.3969/j.issn.1001-5256.2020.09.010
[13]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[14]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023
[15]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[16]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[17]	Lu Ying. Correlation of serum interleukin-33 with HBV DNA load and ALT level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1853-1856. doi: 10.3969/j.issn.1001-5256.2015.11.020
[18]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[19]	Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.
[20]	Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	蒙荫杰，邱华，李旺，王梓塨，朱玟霜，黄鹏. 加味茵陈四逆颗粒联合西医综合疗法治疗乙型肝炎病毒感染相关慢性肝衰竭的效果. 中国医药导报. 2022(05): 146-149+166 .
2.	陆素芳，周红，王丹丹，陈益群，赵红利，张勇杨. MELD联合血小板体积对HBV相关亚急性肝衰竭预后预测作用. 肝胆外科杂志. 2022(01): 20-24 .
3.	许娟，杜粉静，侯静涛，闫涛涛，樊研. MELD评分联合血氨在HBV相关慢加急性肝衰竭90天预后的预测作用. 现代消化及介入诊疗. 2022(06): 742-745 .
4.	王娜. 血清免疫球蛋白检验在肝衰竭患者中的应用意义. 中国医药指南. 2021(34): 106-107+117 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (616) PDF downloads(47)

Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.02.012